No Data
TEDA BIOMEDICAL: Annual Report 2024
TEDA BIOMEDICAL (08189.HK) recommends adopting the 2025 share incentive plan.
On April 25, Gelonghui announced that TEDA BIOMEDICAL (08189.HK) resolved at the Board of Directors meeting to propose the adoption of the 2025 Share Award Plan ("the Plan"), which will be implemented in accordance with the amended Chapter 23 of the GEM Listing Rules effective from January 1, 2023. The Plan must be approved by the Company Shareholders at the upcoming shareholders' meeting to take effect. As of the date of this announcement, the company has no other currently valid and ongoing share plans.
【Brokerage Focus】Guotai Haitong SEC: The impact of USA's tariff increase on the pesticide industry is limited, and changes in the trade pattern of Shenzhen Agricultural Products Group are expected to boost Global market demand.
Gold Wuzhou Finance | Guotai Haitong SEC's Research Reports state that, on one hand, the recent USA tariffs have exempted certain primary raw materials for pesticides, while on the other hand, some leading domestic pesticide companies have already established manufacturing bases in the USA. The firm believes that the tariff increase has limited impact on the pesticide Industry, while the changes in the Global agricultural trade pattern created by this are expected to boost Global pesticide market demand.
TEDA BIOMEDICAL (08189) plans to issue up to 0.1035 billion shares at a discount of approximately 13.79%, raising about 38.3 million HKD.
TEDA BIOMEDICAL (08189) announced that on April 8, 2025 (after the trading period), the company will be in partnership with the placement agent...
Express News | Tianjin TEDA Biomedical Engineering - Zhongtai International Securities to Procure to Not Less Than 6 Placees for Co
TEDA BIOMEDICAL: ANNOUNCEMENT ON ANNUAL RESULTS FOR 2024